PHASE II TRIAL OF HYD-SULFATE AZD6244 [NSC 748727] IN PATIENTS WITH BRAF OR NRAS MUTATED MELANOMAS (NCI 8252).

Trial Profile

PHASE II TRIAL OF HYD-SULFATE AZD6244 [NSC 748727] IN PATIENTS WITH BRAF OR NRAS MUTATED MELANOMAS (NCI 8252).

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2015

At a glance

  • Drugs Selumetinib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 May 2013 Planned end date changed from 1 Jun 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 02 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top